The Europe Gastric Cancer Market would witness market growth of 16.9% CAGR during the forecast period (2023-2029).
Gastric cancer, particularly tumors in the lower stomach region, appears mostly caused by infection with Helicobacter pylori (H pylori) bacteria. Atrophic gastritis and other precancerous alterations to the stomach's inner lining may result after a long-term infection with this bacterium. Being overweight or obese is associated with a higher chance of developing this type of cancer, which affects the upper portion of the stomach next to the esophagus.
People are more inclined to seek medical attention and get examined for the disease as they become more aware of the risk factors linked to gastric cancer, like tobacco use, diet, and family history. With growing awareness, more cases of gastric cancer can be identified at an earlier stage, which is essential for effective treatment and better patient outcomes. It is anticipated that this will lead to a rise in demand for diagnostic and therapeutic alternatives, such as medication, surgery, and radiation therapy. As a result, there will be more participants in the gastric cancer market in the future as healthcare awareness rises.
21% of adults in England regularly consume alcohol at levels that increase their risk of sickness (higher-risk drinkers and drinkers at increased risk). Men (25 and 11%, respectively) were found to consume alcohol in harmful amounts more than twice as often as women (on average). Similar to this, it was discovered that 5% of men and 3% of women drank alcohol at amounts associated with higher risks (5% consumed over 50 units and 3% consumed over 35 units, respectively). Adults in the least deprived areas had a lower likelihood than those in the least deprived areas of exceeding 14 units of alcohol in a typical week. Although younger people are less likely to drink than any other age group, data indicate that on their busiest drinking day, their intake is more likely to be higher than that of older people.
The Germany market dominated the Europe Gastric Cancer Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $456 million by 2029. The UK market is anticipated to grow at a CAGR of 15.9% during (2023 - 2029). Additionally, The France market would experience a CAGR of 17.8% during (2023 - 2029).
Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy & Surgery. Based on Disease Type, the market is segmented into Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor, Lymphoma and Others. Based on Distribution Channel, the market is segmented into Specialty & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Gastric Cancer Market is Projected to reach USD 6.9 Billion by 2029, at a CAGR of 17.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
By Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy & Surgery
By Disease Type
- Adenocarcinoma
- Carcinoid Tumor
- Gastrointestinal Stromal Tumor
- Lymphoma
- Others
By Distribution Channel
- Specialty & Retail Pharmacies
- Hospital Pharmacies
- Others
By Drug Class
- PD-1/PD-L1 Inhibitors
- HER2 Antagonists
- VEGFR2 Antagonists
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer, Inc.
- Viatris, Inc. (Mylan N.V.)
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Celltrion Healthcare Co., Ltd.
- Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Gastric Cancer Market, by Route of Administration
1.4.2 Europe Gastric Cancer Market, by Treatment Type
1.4.3 Europe Gastric Cancer Market, by Disease Type
1.4.4 Europe Gastric Cancer Market, by Distribution Channel
1.4.5 Europe Gastric Cancer Market, by Drug Class
1.4.6 Europe Gastric Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals & Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Europe Gastric Cancer Market by Route of Administration
4.1 Europe Injectable Market by Country
4.2 Europe Oral Market by Country
Chapter 5. Europe Gastric Cancer Market by Treatment Type
5.1 Europe Chemotherapy Market by Country
5.2 Europe Targeted Therapy Market by Country
5.3 Europe Immunotherapy Market by Country
5.4 Europe Radiation Therapy & Surgery Market by Country
Chapter 6. Europe Gastric Cancer Market by Disease Type
6.1 Europe Adenocarcinoma Market by Country
6.2 Europe Carcinoid Tumor Market by Country
6.3 Europe Gastrointestinal Stromal Tumor Market by Country
6.4 Europe Lymphoma Market by Country
6.5 Europe Others Market by Country
Chapter 7. Europe Gastric Cancer Market by Distribution Channel
7.1 Europe Specialty & Retail Pharmacies Market by Country
7.2 Europe Hospital Pharmacies Market by Country
7.3 Europe Others Market by Country
Chapter 8. Europe Gastric Cancer Market by Drug Class
8.1 Europe PD-1/PD-L1 Inhibitors Market by Country
8.2 Europe HER2 Antagonists Market by Country
8.3 Europe VEGFR2 Antagonists Market by Country
8.4 Europe Others Market by Country
Chapter 9. Europe Gastric Cancer Market by Country
9.1 Germany Gastric Cancer Market
9.1.1 Germany Gastric Cancer Market by Route of Administration
9.1.2 Germany Gastric Cancer Market by Treatment Type
9.1.3 Germany Gastric Cancer Market by Disease Type
9.1.4 Germany Gastric Cancer Market by Distribution Channel
9.1.5 Germany Gastric Cancer Market by Drug Class
9.2 UK Gastric Cancer Market
9.2.1 UK Gastric Cancer Market by Route of Administration
9.2.2 UK Gastric Cancer Market by Treatment Type
9.2.3 UK Gastric Cancer Market by Disease Type
9.2.4 UK Gastric Cancer Market by Distribution Channel
9.2.5 UK Gastric Cancer Market by Drug Class
9.3 France Gastric Cancer Market
9.3.1 France Gastric Cancer Market by Route of Administration
9.3.2 France Gastric Cancer Market by Treatment Type
9.3.3 France Gastric Cancer Market by Disease Type
9.3.4 France Gastric Cancer Market by Distribution Channel
9.3.5 France Gastric Cancer Market by Drug Class
9.4 Russia Gastric Cancer Market
9.4.1 Russia Gastric Cancer Market by Route of Administration
9.4.2 Russia Gastric Cancer Market by Treatment Type
9.4.3 Russia Gastric Cancer Market by Disease Type
9.4.4 Russia Gastric Cancer Market by Distribution Channel
9.4.5 Russia Gastric Cancer Market by Drug Class
9.5 Spain Gastric Cancer Market
9.5.1 Spain Gastric Cancer Market by Route of Administration
9.5.2 Spain Gastric Cancer Market by Treatment Type
9.5.3 Spain Gastric Cancer Market by Disease Type
9.5.4 Spain Gastric Cancer Market by Distribution Channel
9.5.5 Spain Gastric Cancer Market by Drug Class
9.6 Italy Gastric Cancer Market
9.6.1 Italy Gastric Cancer Market by Route of Administration
9.6.2 Italy Gastric Cancer Market by Treatment Type
9.6.3 Italy Gastric Cancer Market by Disease Type
9.6.4 Italy Gastric Cancer Market by Distribution Channel
9.6.5 Italy Gastric Cancer Market by Drug Class
9.7 Rest of Europe Gastric Cancer Market
9.7.1 Rest of Europe Gastric Cancer Market by Route of Administration
9.7.2 Rest of Europe Gastric Cancer Market by Treatment Type
9.7.3 Rest of Europe Gastric Cancer Market by Disease Type
9.7.4 Rest of Europe Gastric Cancer Market by Distribution Channel
9.7.5 Rest of Europe Gastric Cancer Market by Drug Class
Chapter 10. Company Profiles
10.1 Novartis AG
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.2 Pfizer, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional & Segmental Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.3 Viatris, Inc. (Mylan N.V.)
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals & Trials:
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.4.5.2 Product Launches and Product Expansions:
10.5 Eli Lilly And Company
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 Recent strategies and developments:
10.5.5.1 Approvals & Trials:
10.5.5.2 Partnerships, Collaborations, and Agreements:
10.6 Merck & Co., Inc.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 Teva Pharmaceutical Industries Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.7.5 Recent strategies and developments:
10.7.5.1 Product Launches and Product Expansions:
10.7.5.2 Approvals & Trials:
10.7.5.3 Partnerships, Collaborations, and Agreements:
10.8 Bristol Myers Squibb Company
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals & Trials:
10.9 Celltrion Healthcare Co., Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Recent strategies and developments:
10.9.3.1 Partnerships, Collaborations, and Agreements:
10.10. Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Approvals & Trials:
10.10.5.2 Product Launches and Product Expansions:
TABLE 1 Europe Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 2 Europe Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Gastric Cancer Market
TABLE 4 Product Launches And Product Expansions– Gastric Cancer Market
TABLE 5 Approvals & Trials – Gastric Cancer Market
TABLE 6 Europe Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 7 Europe Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 8 Europe Injectable Market by Country, 2019 - 2022, USD Million
TABLE 9 Europe Injectable Market by Country, 2023 - 2029, USD Million
TABLE 10 Europe Oral Market by Country, 2019 - 2022, USD Million
TABLE 11 Europe Oral Market by Country, 2023 - 2029, USD Million
TABLE 12 Europe Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 13 Europe Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 14 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 15 Europe Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 16 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 17 Europe Targeted Therapy Market by Country, 2023 - 2029, USD Million
TABLE 18 Europe Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 19 Europe Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 20 Europe Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
TABLE 21 Europe Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
TABLE 22 Europe Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 23 Europe Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 24 Europe Adenocarcinoma Market by Country, 2019 - 2022, USD Million
TABLE 25 Europe Adenocarcinoma Market by Country, 2023 - 2029, USD Million
TABLE 26 Europe Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
TABLE 27 Europe Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
TABLE 28 Europe Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
TABLE 29 Europe Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
TABLE 30 Europe Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 31 Europe Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 32 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 33 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 34 Europe Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 35 Europe Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 36 Europe Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 37 Europe Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 38 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 39 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 40 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 41 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 42 Europe Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 43 Europe Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 44 Europe PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 45 Europe PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 46 Europe HER2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 47 Europe HER2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 48 Europe VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 49 Europe VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 50 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 51 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 52 Europe Gastric Cancer Market by Country, 2019 - 2022, USD Million
TABLE 53 Europe Gastric Cancer Market by Country, 2023 - 2029, USD Million
TABLE 54 Germany Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 55 Germany Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 56 Germany Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 57 Germany Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 58 Germany Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 59 Germany Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 60 Germany Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 61 Germany Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 62 Germany Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 63 Germany Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 64 Germany Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 65 Germany Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 66 UK Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 67 UK Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 68 UK Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 69 UK Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 70 UK Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 71 UK Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 72 UK Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 73 UK Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 74 UK Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 75 UK Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 76 UK Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 77 UK Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 78 France Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 79 France Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 80 France Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 81 France Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 82 France Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 83 France Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 84 France Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 85 France Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 86 France Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 87 France Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 88 France Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 89 France Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 90 Russia Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 91 Russia Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 92 Russia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 93 Russia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 94 Russia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 95 Russia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 96 Russia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 97 Russia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 98 Russia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 99 Russia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 100 Russia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 101 Russia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 102 Spain Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 103 Spain Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 104 Spain Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 105 Spain Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 106 Spain Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 107 Spain Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 108 Spain Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 109 Spain Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 110 Spain Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 111 Spain Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 112 Spain Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 113 Spain Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 114 Italy Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 115 Italy Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 116 Italy Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 117 Italy Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 118 Italy Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 119 Italy Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 120 Italy Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 121 Italy Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 122 Italy Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 123 Italy Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 124 Italy Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 125 Italy Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 126 Rest of Europe Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 127 Rest of Europe Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 128 Rest of Europe Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 129 Rest of Europe Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 130 Rest of Europe Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 131 Rest of Europe Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 132 Rest of Europe Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 133 Rest of Europe Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 134 Rest of Europe Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 135 Rest of Europe Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 136 Rest of Europe Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 137 Rest of Europe Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 138 Key Information – Novartis AG
TABLE 139 Key Information – Pfizer, Inc.
TABLE 140 key information – Viatris, Inc.
TABLE 141 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 142 Key Information – Eli Lilly And Company
TABLE 143 KEY INFORMATION - Merck & Co., Inc.
TABLE 144 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 145 Key Information – Bristol Myers Squibb Company
TABLE 146 Key Information – Celltrion Healthcare Co., Ltd.
TABLE 147 Key Information – Samsung Biologics Co., Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Recent strategies and developments: Viatris, Inc.
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 6 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 7 Recent strategies and developments: Samsung Biologics Co., Ltd.